BioMed Research International

Special Issue on Therapeutic Potential of Neurokinin-ô Receptor Antagonists CALL FOR PAPERS (SP) is a member of the tachykinin family of peptides that binds Lead Guest Editor preferentially to the neurokinin-Ô receptor (NK-ÔR). e SP/NK-ÔR system is Miguel Muñoz, Virgen del Rocío widely distributed in the whole body, including body žuids, and hence SP is University Hospital, Sevilla, Spain ubiquitous throughout the human body. is system is involved in the molecular [email protected] base of many pathophysiological actions: cancer, metastasis, pruritus, cough, inžammation, pain, rheumatoid arthritis, stress, depression, alcohol addiction, Guest Editors emesis, seizure, schizophrenia, bipolar disorder, asthma, irritable bowel syndrome, Rišat Mehboob, University of Lahore, neuronal degeneration, migraine, cardiomyopathy, cholestasis, platelet aggregation, Lahore, Pakistan and bacteria/viral infection. is means that an in-depth knowledge of the SP/NK-ÔR mehboob.riš[email protected] system is the key for a better understanding/management of human diseases. Rafael Coveñas, University of Because an upregulation occurs in the SP/NK-ÔR system of these diseases, NK- Salamanca, Salamanca, Spain ÔR is a pivotal target for their treatment and hence the use of nonpeptide NK-ÔR [email protected] antagonists (e.g., , ) is a valuable therapeutic tool to treat these diseases. Non-peptide NK-ÔR antagonists, even administered at a high dose, Submission Deadline are well tolerated, safe, and do not show serious side-ešects. However, although the Friday, â August òýòÔ SP/NK-ÔR system is involved in many pathologies, to date, the use of only ve NK-ÔR antagonists (aprepitant, fosaprepitant, , , fosnetupitant) has been Publication Date approved in humans. Preclinical studies have shown the benecial ešects of NK-ÔR December òýòÔ antagonists in the treatment of diseases, but unfortunately, these benecial ešects were oŸen not found in human clinical trials and hence its therapeutic potential is currently minimized. Many reasons have explained these ndings; one of them is the dose administered of the NK-ÔR antagonist. Unfortunately, in many pathologies (e.g., cancer, viral infection) pharmacological therapy has not fully exploited the many possible therapies ošered by nonpeptide NK-ÔR antagonists. For example, by increasing both the number of days on which nonpeptide NK-ÔR antagonists are administered and by increasing the dose of these antagonists. In addition, more preclinical/clinical studies are required to fully determine the safety/e›cacy of some NK-ÔR antagonists (e.g., , rolapitant, serlopitant) in diseases in which the SP/NK-Ô receptor system is involved.

e aim of this Special Issue is to solicit original research articles, as well as review articles, highlighting basic, preclinical, and clinical research lines on the involvement of the SP/NK-Ô receptor system in human pathology, and on the promising use of nonpeptide NK-ÔR antagonists in clinical practice. Moreover, this Special Issue hopes to explore the potential of NK-ÔR antagonists in dišerent pathological conditions, and to increase the knowledge on the SP/NK-ÔR system. Submissions focusing on in-depth knowledge of the SP/NK-ÔR system to better understand how to handle human diseases are particularly encouraged.

Potential topics include but are not limited to the following: Respiratory diseases Inžammatory diseases Pathological basis of disease Cancer progression and metastasis Chemotherapy-induced nausea and vomiting Infection Postoperative therapy e genetic basis of disease Neurological and neuropathological conditions

Authors can submit their manuscripts through the Manuscript Tracking System at https://review.hindawi.com/submit?specialIssue= ÀçòÔç.

Papers are published upon acceptance, regardless of the Special Issue publication date.